Lymphoma Action are helping with a National Institute for Health and Care Excellence (NICE) assessment of the targeted drug brentuximab vedotin for treating people with cutaneous T-cell lymphoma (CTCL). NICE are currently looking at the evidence to decide whether to make brentuximab vedotin available for use on the NHS for people with CTCL.
If you are living with CTCL, your views would really help us to capture what life is like living with these conditions, and what the advantages and disadvantages of the treatment might be. We would like to supply NICE with insight from people living with this condition as it may prove helpful as they consider their assessment.
Get in touch with our Senior Medical Writer, Dr Becky Salisbury, if you would like to find out more about how you can be involved in this important assessment: email@example.com